Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2009 Sep 14.

Published in final edited form as: Diabetes Care. 2007 Apr 6;30(7):1709–1716. doi: 10.2337/dc06-1549

Total GLP-1 (A), GIP (B), and active GLP-1 (C) levels during OGTTs in patients before (♦) and after (■) RY-GBP (A) and in control subjects (▲) and incretin effect on insulin secretion (D) in control subjects (□), patients before RY-GBP (), and patients after RY-GBP (■). The incretin effect was calculated by comparing the insulin response to oral and matched IV glucose loads. Data are means±SEM. *P<0.05 compared with patients before RY-GBP. #P < 0.05 compared with control subjects.

Inline graphic — Total GLP-1 (A), GIP (B), and active GLP-1 (C) levels during OGTTs in patients before (♦) and after (■) RY-GBP (A) and in control subjects (▲) and incretin effect on insulin secretion (D) in control subjects (□), patients before RY-GBP (), and patients after RY-GBP (■). The incretin effect was calculated by comparing the insulin response to oral and matched IV glucose loads. Data are means±SEM. *P<0.05 compared with patients before RY-GBP. #P < 0.05 compared with control subjects.